Skip to content

Therapeutic Effects and Mechanisms of the Mindfulness Life Group in a Population with Subclinical Depression

Therapeutic Effects and Mechanisms of the Mindfulness Life Group in a Population with Subclinical Depression

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082234
Enrollment
Unknown
Registered
2024-03-25
Start date
2024-03-25
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subclinical depression

Interventions

Mindfulness Life Group- Intervention Group:Participate in the Mindfulness Life Group intervention (8-10 weeks, once a week, 180 mins per session) immediately after the baseline test.
Mindfulness Life Group- Waitlist Group:Following the baseline test, wait for 8-10 weeks before participating in the Mindfulness Life Group intervention.

Sponsors

Institute of Psychology, Chinese Academy of Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1) Age between 18-35 years old; 2) BMI: 18-30kg/m2; 3) High level of cooperation and a strong willingness to participate. 4) Subclinical depression as assessed by a combination of the Hamilton Clinical Interview and the Depression Self-Rating Scales (with 2 or more depressive symptoms but fewer than 5 of the DSM diagnostic criteria for depression, with a duration of at least two weeks, with impaired social functioning but not meeting the diagnostic criteria for mild depression, major depression, or dysphoric mood disorder); scores of 9-20 on the PHQ-9 Scale; BDI scores >=8; HAMD scores 7-17. 5) No history of psychiatric illness or psychiatric disease other than depressive or anxiety states; 6) Right-handed

Exclusion criteria

Exclusion criteria: 1) Patients diagnosed with major depressive disorder (particularly those who are receiving antidepressants), schizoaffective disorder, schizophrenia, bipolar disorder, mental retardation, pervasive developmental disorder, delirium, dementia, memory impairment, or other cognitive disorders consistent with the diagnostic manifestations of DSM-5; 2) Individuals who showed dangerous suicidal ideation or suicide attempt behavior during the clinical interview; 3) Currently in the course of a severe stressful event; 4) Have a history of addiction (including substance abuse, internet addiction, etc.)

Design outcomes

Primary

MeasureTime frame
level of depression;depression severity;level of anxiety;regulatory emotional self-efficacy;ruminative response;level of mindfulness ;interoceptive awareness;alexithymia;loneliness;posttraumatic growth;perceived social support;sleep quality (subjective);sleep duration and PPG during sleep (objective);self-compassion;self-esteem;self-efficacy;mental flexibility;cognitive flexibility;Attention to Positive and Negative Information;emotional attention;attentional control (subjective);cognitive control/response inhibition;sense of well-being;life satisfaction;psychological resilience;experiential avoidance;emotional working memory;PPG;motor activity (ACC/GYRO);self-generated thoughts;number of anwersing/dialing out phone calls and length of calls per day;number of receiving/sending messages per day;number of mobile phone apps used per day;

Secondary

MeasureTime frame
cognitive emotion regulation strategies;experience of pleasure;behavioral inhibition/ activation;childhood trauma;trait anxiety ;emotional contagion ;co-rumination ;interpersonal reactivity (empathy ability);skin temperature;daily moods;time (duration) of mobile phone use per day;number (frequency) of mobile phone use per day;

Countries

China

Contacts

Public ContactChaogan Yan

Institute of Psychology, Chinese Academy of Sciences

ycg.yan@gmail.com+86 10 6410 1582

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026